Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per 100,000 person-years. It is characterized by severe proteinuria and ...

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of nephrotic syndrome in children in Japan, also improves disease management in ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what about patients ...

A trial evaluated whether rituximab can attain remission in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS).

Patients with nephrotic syndrome were far more likely than healthy controls to suffer end-stage kidney disease, particularly if they had focal segmental glomerulosclerosis or membranous nephropathy.

Please provide your email address to receive an email when new articles are posted on . Compared with a cohort free of kidney disease, patients with primary nephrotic syndrome were nearly 20-times ...

– Gazyva versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 – – If approved, Gazyva could help children and young adults ...

Topline data were announced from a phase 3 study evaluating obinutuzumab in patients between 2 and 25 years of age with idiopathic nephrotic syndrome.

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the Phase III INShore study of Gazyva ® ...